natgillin/translations-raw huggingface dataset:
Following the application of ingenol mebutate, most patients (>95%) experienced one or more local skin response(s).
Po nanosu gela z ingenol mebutatom se je pri večini bolnikov (> 95 %) pojavil en ali več lokalnih kožnih odzivov.
Following the application of Kentera, oxybutynin plasma concentration increases for approximately 24 to 48 hours, reaching average maximum concentrations of 3 to 4 ng/ml.
Po nanosu obliža Kentera naraste koncentracija oksibutinina v plazmi za približno 24 do 48 ur in doseže povprečno maksimalno koncentracijo od 3 do 4ng/ml.
Following the assessment of the integrated safety data from the clinical trial database, the PRAC agreed with the changes proposed.
Po oceni združenih podatkov o varnosti zdravila, pridobljenih iz podatkovne baze kliničnega preskušanja, se je odbor PRAC strinjal s predlaganimi spremembami.
Following the booster dose, 96.6 % of toddlers developed anti-HBs titres equal to or greater than 10 mIU/ml.
Po obnovitvenem odmerku je 96,6 % malčkov razvilo titre proti- HBs najmanj 10 mIU/ml.
Following the discontinuation of ciclosporin therapy, a target trough range of 12 to 20 ng/mL (chromatographic assay) is recommended.
Po ukinitvi zdravljenja s ciklosporinom je priporočeni razpon najnižjih koncentracij v stanju dinamičnega ravnovesja od 12 do 20 ng/ml (kromatografska metoda).
Following the dose regimen of 8 mg/kg every 2 weeks, the geometric means of ramucirumab Cmin were 49.5 μg/ml (range of 6.3-228 μg/ml) and 74.4 μg/ml (range of 13.8-234 μg/ml) prior to administration of the fourth and seventh dose, respectively of ramucirumab given as a single agent, in serum from patients with advanced gastric cancer.
Po režimu odmerjanja 8 mg/kg vsaka 2 tedna so bile v serumu bolnikov z napredovalim rakom želodca dosežene geometrične srednje vrednosti ramucirumaba Cmin 49,5 μg/ml (obseg 6,3-228 μg/ml) in 74,4 μg/ml (obseg 13,8-234 μg/ml) pred dajanjem četrtega in sedmega odmerka, ko je bil ramucirumab dan v obliki monoterapije.
Following the dose regimen of 8 mg/kg ramucirumab every 2 weeks in combination with FOLFIRI, the geometric means of ramucirumab Cmin were 46.3 μg/ml (range of 7.7-119 μg/ml) and 65.1 μg/ml (range of 14.5-205 μg/ml) prior to administration of the third and fifth dose, respectively, in serum from patients with mCRC.
Ob upoštevanju režima odmerjanja 8 mg/kg ramucirumaba vsaka 2 tedna v kombinaciji s shemo FOLFIRI je geometrično povprečje vrednosti Cmin za ramucirumab v serumu bolnikov z metastatskim kolorektalnim rakom znašalo 46,3 μg/ml (razpon 7,7–119 μg/ml) in 65,1 μg/ml (razpon 14,5– 205 μg/ml) pred dajanjem tretjega oziroma petega odmerka.
Following the dose titration period, the child’s sialorrhoea should be monitored, in conjunction with the carer at no longer than 3 monthly intervals, to assess changes in efficacy and/or tolerability over time, and the dose adjusted accordingly.
Po obdobju titriranja odmerka morate skupaj z skrbnikom na vsaj vsake tri mesece spremljati otrokovo sialorejo, da ocenite postopne spremembe učinkovitosti in/ali prenašanja, in odmerek ustrezno prilagoditi.
Following the end of the INCIVO treatment, please see the ribavirin package leaflet regarding continued contraception requirements.
Za navodila o prepreprečevanju nosečnosti po koncu zdravljenja z zdravilom INCIVO glejte navodilo za uporabo ribavirina.
Following the finger extension procedure(s) and fitting patient with a splint (with treated joint in maximum extension), patients should be instructed to:
Po postopku (postopkih) iztegovanja prstov in namestitvi opornice (tako, da je zdravljen sklep v maksimalni ekstenziji) je treba bolnikom naročiti:
Following the first and second infusion, if the patient does not experience a severe adverse drug reaction (ADR), pre-medication with a corticosteroid for subsequent infusions may either be reduced or omitted, at the discretion of the physician.
Če bolnik med prvim in med drugim infundiranjem nima hudih neželenih učinkov zdravila, je mogoče pri poznejših infundiranjih premedikacijo s kortikosteroidom po zdravnikovi presoji zmanjšati ali opustiti.
Following the first dose of tenofovir disoproxil fumarate in fed patients, the median Cmax in serum ranged from 213 to 375 ng/ml.
Po vnosu prvega odmerka dizoproksiltenofovirijevega fumarata je vrednost mediane Cmax v serumu pri sitih bolnikih znašala od 213 do 375 ng/ml.
Following the first four infusions, if the patient experiences no major IRRs, these inhaled post-infusion medications may be discontinued at the discretion of the physician.
Če po prvih štirih infuzijah ne pride do hudih transfuzijskih reakcij, je po zdravnikovi presoji mogoče prenehati z odmerjanjem navedenih inhalacijskih zdravil.
Following the initial administration, ORENCIA should be given 2 and 4 weeks after the first infusion, then every 4 weeks thereafter.
Po začetni aplikaciji mora bolnik zdravilo ORENCIA prejeti 2 in 4 tedne po prvem infundiranju, nato pa na vsake 4 tedne.
Following the introduction of Prevenar and subsequently Prevenar 13 there was a decline in incidence from 2.1 to 0.1 cases per 1000 children (95%) for the Prevenar serotypes plus serotype 6A and a decline in incidence from 0.9 to 0.1 cases per 1000 children (89%) for the additional serotypes 1, 3, 5,
Po uvedbi cepiva Prevenar in pozneje cepiva Prevenar 13 so ugotovili zmanjšanje incidence z 2,1 na 0,1 primera na 1.000 otrok (95 %) za serotipe cepiva Prevenar in serotip 6A ter zmanjšanje incidence z 0,9 na 0,1 primera na 1.000 otrok (89 %) za dodatne serotipe 1, 3, 5, 7F in 19A, ki jih vsebuje cepivo
Following the last weekly infusion, Cmax increased in a greater than dose-proportional manner, consistent with target mediated drug disposition.
Cmax po zadnjem od odmerkov, ki so jih prejemali enkrat tedensko, je naraščala bolj kot sorazmerno z višino odmerka, kar je v skladu s tarčno posredovanim razporejanjem zdravila.
Following the meal, samples of your breath will be taken.
Potem vam bodo vzeli vzorce izdihanega zraka.
Following the reprocessing of cases using a new methodology as requested in the recent pharmacovigilance inspection, 9 events of ‘rash’ which occurred in 2 patients were identified in the safety database.
Po ponovni obdelavi primerov po novi metodologiji, kot je bilo zahtevano pri zadnjem farmakovigilančnem pregledu, so v zbirki podatkov o varnosti ugotovili 9 primerov »izpuščaja«, ki so se pojavili pri 2 bolnikih.
Following the review of the signal assessment report (SSAR), the Innovator MAH confirmed the possible association between levetiracetam and acute kidney injury.
Po pregledu poročila o oceni varnosti signala (SSAR), je imetnik dovoljenja za promet z inovativnim zdravilom potrdil možno povezavo med levetiracetamom in akutno poškodbo ledvic.
Following the second infusion, the dose of intravenous corticosteroid may be reduced (methylprednisolone 60 mg) at the discretion of the physician.
Po drugi infuziji je mogoče po zdravnikovi presoji znižati odmerek intravenskega kortikosteroida (odmerek metilprednizolona na 60 mg).
Following the second initiation dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle.
Po drugem začetnem odmerku lahko mesečni vzdrževalni odmerek injiciramo v deltoidno ali glutealno mišico.
Following the start of daratumumab treatment, none of the patients tested positive for anti-daratumumab antibodies.
Po začetku zdravljenja z daratumumabom prisotnosti protiteles proti daratumumabu niso potrdili.
Following the surgery, the patient should receive antibiotics and an appropriate anti- inflammatory medicine.
Po kirurškem posegu je treba bolniku dajati antibiotike in ustrezno protivnetno zdravilo.
Following the widespread use of HEXAVAC, additional undesirable effects have been reported: Among reactions found at the injection site, itching and hives have been also reported.
Po začetku splošne uporabe HEXAVAC-a so poročali o dodatnih neželenih učinkih: Med reakcijami na mestu vbrizganja so poročali tudi o srbečici in izpuščajih.
Following therapeutic doses, approximately 10% is found excreted in the urine as salicylic acid, 75% as salicyluric acid, 10% phenolic- and 5% acyl- glucuronides of salicylic acid.
Po terapevtskih odmerkih se približno 10 % izloči v urinu kot salicilna kislina, 75 % kot salicilurična kislina, 10 % kot fenolni glukuronid in 5 % kot acilglukuronid salicilne kisline.
Following these initial 4 weeks of therapy, dogs should be weighed monthly during treatment with the veterinary medicinal product and dose adjustments are made monthly according to effect as described below.
Po začetnih 4 tednih zdravljenja je potrebno pse med zdravljenjem mesečno tehtati in mesečno prilagajati odmerek glede na učinek, ki je opisan spodaj.
Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie’s disease are reduced.
Po prekinitvi plaka se deformacija ukrivljenosti penisa in težave, ki jih bolniku povzroča Peyroniejeva bolezen, zmanjšajo.
Following this dose conversion, 91 study patients (mean age: 64.1 years; 75% male patients) were randomized to receive Numient followed by pre- study LCE or vice versa.
Po zamenjavi odmerka so 91 bolnikov v študiji (povprečna starost: 64,1 leta; 75 % moških bolnikov) randomizirali, tako da so prejemali zdravilo Numient in nato predštudijsko zdravljenje z LCE ali obratno.
Following this period, the recommended daily dose should be continued (see section 4.5).
Po tem obdobju moramo nadaljevati s priporočenim dnevnim odmerkom (glejte poglavje 4.5).
Following this period, the recommended daily dose should be continued.
Po tem obdobju moramo nadaljevati s priporočenim dnevnim odmerkom.
Following this, Somavert is given as an injection under the skin of 10 mg once a day.
Zatem se zdravilo Somavert daje v odmerku 10 mg enkrat dnevno z injekcijo pod kožo.
Following topical application of 5-aminolaevulinic acid, the substance is metabolized to protoporphyrin IX, a photoactive compound which accumulates intracellularly in the treated actinic keratosis lesions.
Po topikalni uporabi 5-aminolevulinske kisline se učinkovina presnavlja v protoporfirin IX, fotoaktivno spojino, ki se kopiči v celicah zdravljenih lezij aktinične keratoze.
Following topical application, dinotefuran and pyriproxyfen are partially absorbed through the dog’s skin leading to systemic exposure.
Po kožnem nanosu se dinotefuran in piriproksifen delno absorbirata preko pasje kože, kar vodi k sistemski izpostavitvi.
Following topical application, the two actives rapidly distribute over the body surface of the animal within the first day and were still measurable in different zones of the hair coat one month after treatment.
Po kožnem nanosu se obe zdravilni učinkovini hitro razporedita po površini telesa živali v prvem dnevu in sta bili izmerjeni v različnih predelih dlake še en mesec po nanosu.
Following topical ocular administration of Travoprost 40 µg/mL eye drops, solution to healthy volunteers, low systemic exposure to active free acid was demonstrated.
Po topikalni okularni uporabi kapljic za oko s travoprostom v odmerku 40 µg/ml pri zdravih prostovoljcih so ugotovili majhno sistemsko izpostavljenost aktivni prosti kislini.
Following toxic doses (1020 g), the plasma half-life may be increased to over 20 hours.
Po toksičnih odmerkih (1020 g) se lahko razpolovni čas v plazmi podaljša na več kot 20 ur.
Following transfer from an animal insulin to human insulin, dose regimen reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Following treatment discontinuation, there is a reversion to the pathological pre-treatment rates of elevated bone resorption associated with postmenopausal osteoporosis.
Po prekinitvi zdravljenja so patološke vrednosti zvišane kostne resorpcije, povezane s postmenopavzno osteoporozo spet enake kot pred začetkom zdravljenja.
Following treatment with a TNF-blocking monoclonal antibody during pregnancy, the antibody has been detected for up to 6 months in the serum of the infant born by the treated woman.
V serumu dojenčka matere, ki je bila v času nosečnosti zdravljena z monoklonskimi protitelesi, ki nevtralizirajo TNF, so še 6 mesecev zaznavali navzočnost teh protiteles.
Following treatment with alitretinoin 0.5% gel, mean plasma concentrations in the female rats were generally below the lower limit of quantitation (5 nMol) and mean plasma concentrations in the male rats were about 200 nMol.
Po zdravljenju z 0,5 % gelom alitretinoina so bile srednje koncentracije v plazmi pri podganjih samicah večinoma pod spodnjo dokazljivo mejo (5 nMol) ter koncentracije v plazmi pri samcih okoli 200nMol.
Following treatment with bendamustine Gazyvaro is then used on its own for the maintenance treatment of FL.
Po zdravljenju z bendamustinom se zdravilo Gazyvaro uporablja samostojno kot vzdrževalno zdravljenje folikularnega limfoma.
Following treatment with FVIII products some patients may develop factor VIII inhibitors, which are antibodies (proteins) that the body’s immune system produces against factor VIII and which can cause the medicine to stop working, resulting in a loss of bleeding control.
Po zdravljenju z zdravili, ki vsebujejo faktor VIII, se lahko pri nekaterih bolnikih pojavijo zaviralci faktorja VIII, ki so protitelesa (beljakovine), ki jih imunski sistem telesa tvori proti faktorju VIII in ki lahko povzročijo, da zdravilo preneha učinkovati, kar privede do izgube nadzora nad krvavitvami.
Following treatment with G-CSF after bone marrow transplantation
Po zdravljenju z G-CSF po presaditvi kostnega mozga
Following twice daily administration of naltrexone / bupropion, naltrexone does not accumulate, while 6-beta-naltrexol accumulates over time.
Po aplikaciji kombinacije naltrekson/bupropion dvakrat dnevno se naltrekson ne akumulira, medtem ko se 6-beta-naltrekson sčasoma akumulira.
Following two intravenous infusions of MabThera at a dose of 1000 mg, two weeks apart, the mean terminal half-life was 20.8 days (range, 8.58 to 35.9 days), mean systemic clearance was 0.23 l/day (range, 0.091 to 0.67 l/day), and mean steady-state distribution volume was 4.6 l (range, 1.7 to 7.51 l).
Po dveh intravenskih infuzijah zdravila MabThera v odmerku 1.000 mg v razmiku dveh tednov je bil povprečni končni razpolovni čas 20,8 dni (razpon 8,58 do 35,9 dni), povprečni sistemski očistek je bil 0,23 l/dan (razpon 0,091 do 0,67 l/dan), povprečen volumen distribucije v stanju dinamičnega ravnovesja pa 4,6 l (razpon 1,7 do 7,51 l).
Following use of Elonva, 61 infants were born after an FTET cycle, and 630 infants were born after fresh ART cycles.
Po uporabi zdravila Elonva se je rodilo 61 otrok po FTET ciklu in 630 otrok po ART ciklu s svežimi zarodki.
Following weekly administration of 2 mg prolonged-release exenatide, mean exenatide concentrations exceeded minimal efficacious concentrations (~ 50 pg/ml) in 2 weeks with gradual increase in the average plasma exenatide concentration over 6 to 7 weeks.
Ob tedenskem dajanju 2 mg eksenatida v obliki s podaljšanim sproščanjem, je srednja vrednost koncentracije eksenatida v dveh tednih presegla minimalno učinkovito koncentracijo (~ 50 pg/ml), s postopnim višanjem povprečne plazemske koncentracije eksenatida preko 6 do 7 tednov.
Following widespread use of either GlaxoSmithKline’s combined hepatitis A and hepatitis B vaccines or the monovalent hepatitis A and/or hepatitis B vaccines, the following adverse reactions have additionally been reported.
Po široki uporabi kombiniranih cepiv družbe GlaxoSmithKline proti hepatitisu A in hepatitisu B ali njenih monovalentnih cepiv proti hepatitisu A in/ali hepatitisu B so bili dodatno opisani naslednji neželeni učinki.
Following widespread use of hepatitis B vaccines, in very rare cases, syncope, paralysis, neuropathy, neuritis (including Guillain-Barré syndrome, optic neuritis and multiple sclerosis), encephalitis, encephalopathy, meningitis and convulsions have been reported.
Pri široki uporabi cepiv proti hepatitisu B v zelo redkih primerih poročajo o sinkopi, paralizi, nevropatiji, nevritisu (vključno z Guillain-Barréjevim sindromom, optičnim nevritisem in multiplo sklerozo), encefalitisu, encefalopatiji, meningitisu in konvulzijah.
Following widespread use of the monovalent hepatitis A and/or hepatitis B vaccines, the following undesirable events have additionally been reported in temporal association with vaccination:
Pri spremljanju množične uporabe monovalentnih cepiv proti hepatitisu A in/ali hepatitisu B so dodatno poročali o naslednjih neželenih učinkih, ki so bili časovno povezani s cepljenjem:
Following withdrawal of treatment with Eucreas and LFT normalisation, treatment with Eucreas should not be re-initiated.
Po prekinitvi zdravljenja z zdravilom Eucreas in normalizaciji vrednosti jetrnih testov se zdravljenja z zdravilom Eucreas ne sme ponovno uvesti.
Following your kidney or liver transplant, your body’s immune system will try to reject the new organ.
Po presaditvi ledvice ali jeter bo imunski sistem telesa poskusil zavrniti novi organ.
Following your organ transplant (e.g. liver, kidney, heart), your body’s immune system will try to reject the new organ.
Po presaditvi organa (npr. jeter, ledvic, srca) telo poskuša zavrniti novi organ.
Following your organ transplant (liver, kidney), your body’s immune system will try to reject the new organ.
Po presaditvi organa (jeter, ledvic) telo poskuša zavrniti novi organ.
Fondaparinux 2.5 mg once daily started 6-8 hours postoperatively was compared with enoxaparin 40 mg once daily started 12 hours before surgery, or 30 mg twice daily started 12-24 hours after surgery.
Primerjali so profilakso s fondaparinuksom 2,5 mg enkrat na dan, s pričetkom 6-8 ur po operaciji in enoksaparinom 40 mg enkrat na dan s pričetkom 12 ur pred operacijo ali 30 mg dvakrat na dan s pričetkom 12-24 ur po operaciji.
Fondaparinux 5 mg (body weight < 50 kg), 7.5 mg (body weight  50kg,  100 kg) or 10 mg (body weight >100 kg) SC once daily was compared to unfractionated heparin IV bolus (5,000 IU) followed by a continuous IV infusion adjusted to maintain 1.5–2.5 times aPTT control value.
Primerjali so fondaparinuks v odmerkih 5 mg (telesna masa < 50 kg), 7,5 mg (telesna masa > 50 kg, ≤ 100 kg) ali 10 mg (telesna masa > 100 kg) s.c. enkrat na dan z i.v. bolusom nefrakcioniranega heparina (5.000 i.e.), ki mu je sledila neprekinjena i.v. infuzija, prilagojena tako, da se je vzdrževala 1,5- 2,5-kratna kontrolna vrednost aPTT.
Fondaparinux 5 mg (body weight < 50 kg), 7.5 mg (body weight  50kg,  100 kg) or 10 mg (body weight >100 kg) SC once daily was compared to unfractionated heparin IV bolus (5,000 IU) followed by a continuous IV infusion adjusted to maintain 1.5–2.5 times aPTT control value.
Primerjali so fondaparinuks v odmerkih 5 mg (telesna masa < 50 kg), 7,5 mg (telesna masa > 50 kg, ≤ 100 kg) ali 10 mg (telesna masa > 100 kg) s.c. enkrat na dan z i.v. bolusom nefrakcioniranega heparina (5.000 i.e.), ki mu je sledila neprekinjena i.v. infuzija, prilagojena tako, da se je vzdrževala 1,5-2,5-kratna kontrolna vrednost aPTT.
Fondaparinux 5 mg (body weight < 50 kg), 7.5 mg (body weight  50kg,  100 kg) or 10 mg (body weight >100 kg) SC once daily was compared to unfractionated heparin IV bolus (5,000 IU) followed by a continuous IV infusion adjusted to maintain 1.5–2.5 times aPTT control value.
Primerjali so fondaparinuks v odmerkih 5 mg (telesna masa < 50 kg), 7,5 mg (telesna masa> 50 kg, ≤ 100 kg) ali 10 mg (telesna masa > 100 kg) s.c. enkrat na dan z i.v. bolusom nefrakcioniranega heparina (5.000 i.e.), ki mu je sledila neprekinjena i.v. infuzija, prilagojena tako, da se je vzdrževala 1,5-2,5-kratna kontrolna vrednost aPTT.
Fondaparinux 5 mg (body weight < 50 kg), 7.5 mg (body weight  50kg,  100 kg) or 10 mg (body weight >100 kg) SC once daily was compared to unfractionated heparin IV bolus (5000 IU) followed by a continuous IV infusion adjusted to maintain 1.5–2.5 times aPTT control value..
Primerjali so fondaparinuks v odmerkih 5 mg (telesna masa < 50 kg), 7,5 mg (telesna masa > 50 kg,  100 kg) ali 10 mg (telesna masa > 100 kg) s.c. enkrat na dan z i.v. bolusom nefrakcioniranega heparina (5.000 i.e.), ki mu je sledila neprekinjena i.v. infuzija, prilagojena tako, da se je vzdrževala 1,5-2,5-kratna kontrolna vrednost aPTT.
Fondaparinux does not bind significantly to other plasma proteins, including platelet factor 4 (PF4).
Fondaparinuks se ne veže pomembno na druge proteine plazme, vključno s trombocitnim faktorjem 4 (PF4).
Fondaparinux does not bind to platelet factor 4 and does not cross-react with sera from patients with Heparin Induced Thrombocytopenia (HIT) type II.
Fondaparinuks se ne veže na trombocitni faktor 4 in ne reagira navzkrižno s serumi bolnikov s heparinsko trombocitopenijo (HIT) tipa II,
Fondaparinux does not bind to platelet factor 4 and does not cross-react with sera from patients with Heparin Induced Thrombocytopenia (HIT) type II.
Fondaparinuks se ne veže na trombocitni faktor 4 in ne reagira navzkrižno s serumi bolnikov s trombocitopenijo, povzročeno s heparinom (HIT) tipa II.
Fondaparinux is excreted to 64 – 77 % by the kidney as unchanged compound.
Fondaparinuks se izloča preko ledvic, 64 – 77 % v nespremenjeni obliki.
Fondaparinux is known to be mainly excreted by the kidney.
Znano je, da se fondaparinuks izloča predvsem preko ledvic.
Fondaparinux should be used with caution at a daily dose of 5 mg in this population (see sections 4.2 and 5.2).
V tej skupini je treba fondaparinuks previdno uporabljati v dnevnem odmerku 5 mg (glejte poglavji 4.2 in 5.2).
Fondaparinux should be used with caution in patients who have an increased risk of haemorrhage (see section 4.4).
Pri bolnikih, ki imajo povečano tveganje za krvavitve, moramo fondaparinuks uporabljati previdno. (glejte poglavje 4.4).
Fondaparinux should be used with caution in patients with a history of HIT.
Pri bolnikih, pri katerih se je kdaj pojavila heparinska trombocitopenija (HIT), je treba fondaparinuks uporabljati previdno.
Fondaparinux should be used with caution in patients with a history of HIT.
Pri bolnikih, pri katerih se je kdaj pojavila trombocitopenija, povzročena s heparinom (HIT), je treba fondaparinuks uporabljati previdno.
Food additives (substances with a valid E number approved as additives in
Krmni dodatki (snovi z veljavno E številko odobreni kot dodatki za živila v prehrani ljudi
Food also decreased the Cmax of the active metabolite, 3-hydroxy-anagrelide, by 29%, although it had no effect on the AUC.
Hrana je tudi zmanjšala Cmax aktivnega presnovka, 3-hidroksi-anagrelida, za 29 %, čeprav ni imela vpliva na AUC.
Food and drink do not affect MIRCERA.
Hrana in pijača ne vplivata na zdravilo MIRCERA.
Food and drink has no influence on Dynepo.
Hrana in pijača nimata nobenega učinka na zdravilo.
Food can affect the amount of medicine that gets into your bloodstream, and taking your medicine in a consistent way means that the blood levels of Rapamune remain more stable.
Hrana lahko vpliva na količino zdravila, ki pride v vaš krvni obtok, zato jemanje vašega zdravila na vedno enak način pomeni, da bo koncentracija zdravila Rapamune v vaši krvi bolj stabilna.
Food containing grapefruit or Seville oranges should be avoided during treatment with Kalydeco (see section 4.5).
Med zdravljenjem z zdravilom Kalydeco se moramo izogibati hrani, ki vsebuje grenivke ali grenke pomaranče (glejte poglavje 4.5).
Food containing grapefruit or Seville oranges should be avoided during treatment with Kalydeco as they may affect the way the medicine is absorbed and broken down in the body.
Hrani, ki vsebuje grenivke ali grenke pomaranče, se je med zdravljenjem z zdravilom Kalydeco treba izogibati, saj lahko vpliva na to, kako se zdravilo absorbira in presnavlja v telesu.
Food containing grapefruit or Seville oranges should be avoided during treatment with Kalydeco.
Med zdravljenjem z zdravilom Kalydeco se je treba izogibati hrani, ki vsebuje grenivke ali grenke pomaranče.
Food decreases Cmax by approximately 30 %, increases tmax by approximately 1 hour and has little effect on AUC.
Hrana zniža Cmax za približno 30%, podaljša tmax za približno 1 uro in ima le majhen vpliv na AUC.